KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Autor: Zhi-yong Chen, Jian Su, Yi-Long Wu, Hong-Hong Yan, She-Juan An, Zhimin Huang, Jin-Ji Yang, Wen-Zhao Zhong, Ji-lin Guan, Zhi-Hong Chen, Qiang Nie, Xu-Chao Zhang
Rok vydání: 2012
Předmět:
Zdroj: Annals of Surgical Oncology. 20:1381-1388
ISSN: 1534-4681
1068-9265
DOI: 10.1245/s10434-012-2754-z
Popis: The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan–Meier and Cox models. The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P
Databáze: OpenAIRE
Pro tento záznam nejsou dostupné žádné jednotky.